Be Biopharma Announces First Participant Dosed in BeCoMe-9 Trial of BE-101 in Hemophilia B

Be Bio announces the first participant dosed with BE-101 in the BeCoMe-9 trial for hemophilia B. The Phase 1/2 trial aims to assess safety and preliminary efficacy of BE-101, a first-in-class B Cell Medicine that delivers long-lasting FIX levels without preconditioning. BE-101 has the potential to be a transformative therapeutic option for hemophilia B patients.